KRAS and neoplasm: The MYC-dependent increased sensitivity to anti-mitotic chemotherapeutics in KRASG12D-expressing HeLa cells prompted us to evaluate the possibility of using these widely drugs to selectively kill KRAS-mutant tumours, a strategy previously suggested by others2.